Cabaletta Bio (CABA) Cash from Investing Activities (2019 - 2025)
Cabaletta Bio's quarterly Cash from Investing Activities came in at $49.8 million in Q4 2025, up 310.71% year-on-year from $12.1 million in Q4 2024, and up 199.43% quarter-over-quarter from -$50.1 million in Q3 2025.
Cabaletta Bio has reported Cash from Investing Activities for 7 years, with the latest figure at $49.8 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 310.71% year-over-year to $49.8 million; the trailing twelve-month figure through Dec 2025 stood at -$50.3 million (down 206.3% YoY), and the FY2025 full-year result was -$50.3 million, down 206.3% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at $49.8 million, up from -$50.1 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $49.8 million in Q4 2025, with the low at -$50.1 million in Q3 2025.
- Average Cash from Investing Activities over 5 years is -$2.3 million, with a median of $938000.0 recorded in 2021.
- Year-over-year, Cash from Investing Activities sank 5261.02% in 2023 and soared 18941.54% in 2024.
- Tracing CABA's Cash from Investing Activities over 5 years: stood at $849000.0 in 2021, then tumbled by 137.22% to -$316000.0 in 2022, then soared by 459.49% to $1.1 million in 2023, then soared by 967.25% to $12.1 million in 2024, then surged by 310.71% to $49.8 million in 2025.
- The last three Cash from Investing Activities figures came in at $49.8 million (Q4 2025), -$50.1 million (Q3 2025), and -$49.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | 49.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49.80 Mn |
| Dec 31, 2025 | 49.80 Mn |
| Sep 30, 2025 | -50.08 Mn |
| Sep 30, 2025 | -50.08 Mn |
| Jun 30, 2025 | -49.20 Mn |
| Jun 30, 2025 | -49.20 Mn |
| Mar 31, 2025 | -785,000.00 |
| Mar 31, 2025 | -785,000.00 |
| Dec 31, 2024 | 12.12 Mn |
| Dec 31, 2024 | 12.12 Mn |
| Sep 30, 2024 | 12.25 Mn |
| Sep 30, 2024 | 12.25 Mn |
| Jun 30, 2024 | 23.73 Mn |
| Jun 30, 2024 | 23.73 Mn |
| Mar 31, 2024 | -812,000.00 |
| Mar 31, 2024 | -812,000.00 |
| Dec 31, 2023 | 1.14 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | -65,000.00 |
| Sep 30, 2023 | -65,000.00 |
| Jun 30, 2023 | -48.14 Mn |
| Jun 30, 2023 | -48.14 Mn |
| Mar 31, 2023 | 24.62 Mn |
| Mar 31, 2023 | 24.62 Mn |
| Dec 31, 2022 | -316,000.00 |
| Dec 31, 2022 | -316,000.00 |
| Sep 30, 2022 | 23.91 Mn |
| Sep 30, 2022 | 23.91 Mn |
| Jun 30, 2022 | -898,000.00 |
| Jun 30, 2022 | -898,000.00 |
| Mar 31, 2022 | -49.91 Mn |
| Mar 31, 2022 | -49.91 Mn |
| Dec 31, 2021 | 849,000.00 |
| Dec 31, 2021 | 849,000.00 |
| Sep 30, 2021 | 1.77 Mn |
| Sep 30, 2021 | 1.77 Mn |
| Jun 30, 2021 | 1.03 Mn |
| Jun 30, 2021 | 1.03 Mn |
| Mar 31, 2021 | 2.35 Mn |
| Mar 31, 2021 | 2.35 Mn |
| Dec 31, 2020 | 1.89 Mn |
| Dec 31, 2020 | 1.89 Mn |
| Sep 30, 2020 | 1.47 Mn |
| Sep 30, 2020 | 1.47 Mn |
| Jun 30, 2020 | -11.12 Mn |
| Jun 30, 2020 | -11.12 Mn |
| Mar 31, 2020 | -226,000.00 |
| Mar 31, 2020 | -226,000.00 |
| Dec 31, 2019 | -273,000.00 |
| Dec 31, 2019 | -273,000.00 |
| Sep 30, 2019 | -40,000.00 |
| Sep 30, 2019 | -40,000.00 |
| Jun 30, 2019 | -200,000.00 |
| Jun 30, 2019 | -200,000.00 |
| Mar 31, 2019 | -180,000.00 |
| Mar 31, 2019 | -180,000.00 |